RxDoctor Payments Data

Phuong Truong, PA

Physician Assistant · Albuquerque, NMNPI 1508278276

Payments from drug & device makers

$937in general payments, 2019–2025

Across 35 payments — averaging $26.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$239
  • Lilly USA, LLC$177
  • Ascendis Pharma Endocrinology Inc$140
  • Abbott$104
  • Dexcom, Inc.$95
  • Cequr Corporation$53
  • plus $128 from 5 others

What the payments were for

  • Food & beverage$937100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$937 in reported general payments places this provider in the 75th percentile of 635 physician assistant providers in New Mexico.

See all physician assistant providers in New Mexico

Medicare billing

Part B allowed, 2024
$26,383
Medicare patients
104
Services billed
351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide170$239,306
OzempicSemaglutide152$209,004
JardianceEmpagliflozin80$85,831
MounjaroTirzepatide42$55,301
FarxigaDapagliflozin Propanediol32$40,852
Tresiba Flextouch U-100Insulin Degludec49$36,456
Tresiba Flextouch U-200Insulin Degludec25$28,333
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog37$24,522
TradjentaLinagliptin23$24,017
Lantus SolostarInsulin Glargine,hum.Rec.Anlog147$19,881
Humalog Kwikpen U-100Insulin Lispro75$18,732
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$11,805
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$11,277
LantusInsulin Glargine,hum.Rec.Anlog40$6,813
Novolog FlexpenInsulin Aspart38$5,581

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro$177$299,273238 claims
Sanofi-aventis U.S. LLCLantus$25$6,81340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 635 physician assistant providers in New Mexico.

Other physician assistant in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →